CAMBRIDGE, England, June 14, 2010 /PRNewswire/ -- Executives from Senexis Limited (Cambridge,UK) signed an agreement with O2h (Ahmedabad, India) under which O2h will provide Senexis with chemistry services to support a patent filing on a novel chemical series that have shown potential in pre-clinical models, as disease modifying treatments for Alzheimer's Disease.
Dr. Mark Treherne, CEO of Senexis said that he appreciated O2h's continual support over the last 4 years in being a reliable chemistry partner, providing flexible multi-FTE chemistry support to the company.
Dr David Scopes, CSO at Senexis said "We have had a long collaboration with O2h and are happy that it is supporting us to further our programs into the important stage of patent applications. Senexis is again leveraging O2h's expertise on the synthetic chemistry methodology underpinning our lead compounds."
Sunil Shah, CEO, O2h "We have an incredibly good relationship and I was very happy learn about the positive Senexis data from their pre-clinical studies which allowed the Wellcome Trust to continue supporting this programme."
About Oxygen Healthcare Ltd
O2h is a 5 year old discovery services company co-located in Cambridge, UK and Ahmedabad, India. The Indian operations provide a high level of chemistry expertise while UK office provides project management support. Current clients of O2h include several top 20 pharmaceutical and biotechnology companies in the US, Europe and Japan. O2h adheres to the highest standards of performance with a particular emphasis on rapid interactive communications and delivery speed. Services provided by O2h include FTE-based synthetic chemistry, medicinal chemistry, computational chemistry, full services lab-units and ADME. Further information on O2h can be found at http://www.o2h.com.
About Senexis Limited
Senexis is a drug discovery and development company, dedicated to the discovery of effective treatments and diagnostics for major ageing-related diseases, such as Alzheimer's dementia. It is now widely believed that the misfolding and aggregation of amyloid-like proteins underlies the pathologies of Alzheimer's disease and Senexis has discovered potent and selective compounds that protect cells and tissues from the toxic forms of amyloid. Senexis is now actively seeking development partners and further information on Senexis can be found at http://www.senexis.com.
Contact information: Ekta Ahuja PhD firstname.lastname@example.org OXYGEN HEALTHCARE LTD 23 Cambridge Science Park CB4 0EY Contact: SENEXIS LIMITED Babraham Research Campus Babraham, Cambridge, UK CB22 3AT
|SOURCE Oxygen Healthcare Ltd (O2h)|
Copyright©2010 PR Newswire.
All rights reserved